Keyword search (4,163 papers available)

"Leyton M" Authored Publications:

Title Authors PubMed ID
1 Decriminalization or more treatment? Comparing 2 approaches to the drug overdose crisis Caswell C; Krausz RM; Leyton M; 40541419
CSBN
2 A multimodal neuroimaging study of youth at risk for substance use disorders: Functional magnetic resonance imaging and [18F]fallypride positron emission tomography Nikolic M; Cox SML; Jaworska N; Castellanos-Ryan N; Dagher A; Vitaro F; Brendgen M; Parent S; Boivin M; Côté S; Tremblay RE; Séguin JR; Leyton M; 39725679
CSBN
3 Ending the overdose epidemic by ending the war on drug users: Can this work? Leyton M; Krausz RM; 38383036
CSBN
4 Mesocorticolimbic function in cocaine polydrug users: A multimodal study of drug cue reactivity and cognitive regulation Scala SG; Kang MS; Cox SML; Rosa-Neto P; Massarweh G; Leyton M; 38221806
CSBN
5 Learning from opioid withdrawal: Effects on striatal dopamine (Commentary on Ahn et al., 2023) Leyton M; Nikolic M; 38129315
CSBN
6 Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A; 38006502
PERFORM
7 Cocaine cue-induced mesocorticolimbic activation in cocaine users: Effects of personality traits, lifetime drug use, and acute stimulant ingestion D' Amour-Horvat V; Cox SML; Dagher A; Kolivakis T; Jaworska N; Leyton M; 34463411
CSBN
8 Why did the kitten cross the road? A meditation on positive versus negative reinforcement in addiction. Leyton M 33497168
CSBN
9 Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans. Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestikawy S, Leyton M, Benkelfat C 32559027
CSBN
10 mGlu5 receptor availability in youth at risk for addictions: effects of vulnerability traits and cannabis use. Cox SML, Tippler M, Jaworska N, Smart K, Castellanos-Ryan N, Durand F, Allard D, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl RO, Côté S, Tremblay RE, Séguin JR, Leyton M 32413893
CSBN
11 Extra-striatal D2/3 receptor availability in youth at risk for addiction. Jaworska N, Cox SML, Tippler M, Castellanos-Ryan N, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl RO, Côté SM, Tremblay RE, Séguin JR, Leyton M 32259831
CSBN
12 Cannabis legalization: Did we make a mistake? Update 2019 Leyton M 31452361
PSYCHOLOGY
13 Legalizing marijuana. Leyton M 26898727
CSBN
14 Cocaine cue-induced dopamine release in the human prefrontal cortex. Milella MS, Fotros A, Gravel P, Casey KF, Larcher K, Verhaeghe JA, Cox SM, Reader AJ, Dagher A, Benkelfat C, Leyton M 26900792
CSBN
15 Dopamine and light: effects on facial emotion recognition. Cawley E, Tippler M, Coupland NJ, Benkelfat C, Boivin DB, Aan Het Rot M, Leyton M 28633582
CSBN
16 Are people with psychiatric disorders violent? Leyton M 29688170
CSBN
17 Are people with psychiatric disorders violent? Leyton M 29947604
CSBN
18 Neuroimaging tests for clinical psychiatry: Are we there yet? Leyton M, Kennedy SH 28639935
IMAGING
19 Dopamine cross-sensitization between psychostimulant drugs and stress in healthy male volunteers. Booij L, Welfeld K, Leyton M, Dagher A, Boileau I, Sibon I, Baker GB, Diksic M, Soucy JP, Pruessner JC, Cawley-Fiset E, Casey KF, Benkelfat C 26905412
PSYCHOLOGY
20 Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans. Smart K, Cox SML, Kostikov A, Shalai A, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M 30607444
CSBN
21 Sex differences in [11C]ABP688 binding: a positron emission tomography study of mGlu5 receptors. Smart K, Cox SML, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M 30627817
CSBN
22 Posterior dopamine D2/3 receptors and brain network functional connectivity. Nagano-Saito A, Lissemore JI, Gravel P, Leyton M, Carbonell F, Benkelfat C 28700819
PERFORM

 

Title:Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans.
Authors:Smart KNagano-Saito AMilella MSSakae DYFavier MVigneault ELouie LHamilton AFerguson SSGRosa-Neto PNarayanan SEl Mestikawy SLeyton MBenkelfat C
Link:https://www.ncbi.nlm.nih.gov/pubmed/32559027?dopt=Abstract
DOI:10.1503/jpn.190162
Publication:Journal of psychiatry & neuroscience : JPN
Keywords:
PMID:32559027 Category:J Psychiatry Neurosci Date Added:2020-06-20
Dept Affiliation: CSBN
1 From the Department of Psychiatry, McGill University, Montreal, Que. (Smart, Nagano-Saito, Milella, Sakae, Favier, Vigneault, Louie, Rosa-Neto, El Mestikawy, Leyton, Benkelfat); the Douglas Mental Health University Institute, McGill University, Montreal, Que. (Smart, Sakae, Favier, Vigneault, Rosa-Neto, El Mestikawy); the Department of Cellular and Molecular Medicine, University of Ottawa, Ont. (Hamilton, Ferguson); the McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Que. (Rosa-Neto, Narayanan, Leyton, Benkelfat); the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Que. (Rosa-Neto, Narayanan, Leyton, Benkelfat); and the Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, Que. (Leyton).

Description:

Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans.

J Psychiatry Neurosci. 2020 Jun 19;45(4):190162

Authors: Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestikawy S, Leyton M, Benkelfat C

Abstract

Background: Glutamate transmission is implicated in drug-induced behavioural sensitization and the associated long-lasting increases in mesolimbic output. Metabotropic glutamate type 5 (mGlu5) receptors might be particularly important, but most details are poorly understood.

Methods: We first assessed in mice (n = 51, all male) the effects of repeated dextroamphetamine administration (2.0 mg/kg, i.p.) on locomotor activity and binding of the mGlu5 ligand [3H]ABP688. In a parallel study, in 19 stimulant-drug-naïve healthy human volunteers (14 female) we administered 3 doses of dextroamphetamine (0.3 mg/kg, p.o.) or placebo, followed by a fourth dose 2 weeks later. We measured [11C]ABP688 binding using positron emission tomography before and after the induction phase. We assessed psychomotor and behavioural sensitization using speech rate, eye blink rate and self-report. We measured the localization of mGlu5 relative to synaptic markers in mouse striatum using immunofluorescence.

Results: We observed amphetamine-induced psychomotor sensitization in mice and humans. We did not see group differences in mGlu5 availability following 3 pre-challenge amphetamine doses, but group differences did develop in mice administered 5 doses. In mice and humans, individual differences in mGlu5 binding after repeated amphetamine administration were negatively correlated with the extent of behavioural sensitization. In drug-naïve mice, mGlu5 was expressed at 67% of excitatory synapses on dendrites of striatal medium spiny neur.

Limitations: Correlational results should be interpreted as suggestive because of the limited sample size. We did not assess sex differences.

Conclusion: Together, these results suggest that changes in mGlu5 availability are not part of the earliest neural adaptations in stimulant-induced behavioural sensitization, but low mGlu5 binding might identify a higher propensity for sensitization.

PMID: 32559027 [PubMed - as supplied by publisher]





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University